Post

New research · Ophthalmology
American journal of ophthalmology · 17h
StudyAmerican journal of ophthalmology · 2026

Interferon Alpha-2a as Treatment for Primary Acquired Melanosis With Atypia and for Primary Acquired Melanosis With Atypia Surrounding Conjunctival Melanoma.

Daniela Vaisman, Jacob Pe'er, Maya Eiger-Moscovich … Shahar Frenkel
Read paper
OphthalmologyStudy

Topical interferon alfa-2a produced complete clinical response in most primary acquired melanosis with atypia cases.

Interferon Alpha-2a as Treatment for Primary Acquired Melanosis With Atypia and for Primary Acquired Melanosis With Atypia Surrounding Conjunctival Melanoma.

Daniela Vaisman … Shahar Frenkel
American journal of ophthalmology · 2026
Purpose

To report on topical treatment with interferon (interferon) alfa-2a for conjunctival primary acquired melanosis (primary acquired melanosis) with atypia.

Methods

Received topical interferon α-2a, interferon α-2b, or pegylated interferon α-2a.

n = 12 patients
93%
Results
93%
treatment cleared the abnormal cells completely in nearly all patients
n = 12 patients
More results

The average PFS was 52.5 months (4.3 years), with only one patient experiencing recurrence after 13 months.

Treatment was well tolerated; five patients reported mild adverse effects, including dry eye, redness, and blurred vision.

Two patients experienced more severe side effects, leading to treatment discontinuation.

More results

No limbal stem cell damage was observed in patients treated with interferon alone.

“
Conclusion · 1 of 2

Topical interferon α-2a is safe and effective for treating primary acquired melanosis with atypia and for primary acquired melanosis with atypia surrounding conjunctival melanoma that arises from primary acquired melanosis with atypia, with high response rates and little to no toxicity.

Conclusion · 2 of 2

Its similarity to interferon α-2b and safety profile make interferon α-2a a good alternative. Further large-scale, controlled studies are needed to validate these findings and their role in clinical practice.

Read paper
0 comments

No comments yet. Be the first.

Related papers

LatestFoundational
Cross-sectional
44.1%
had too much homocysteine in the blood, a far larger share than in dry AMD or healthy eyes
Cohort Study
92.3%
most laser-treated eyes had a favorable eye-structure outcome
Cohort Study
56%
lost three or more lines on the eye-chart vision test
Cohort Study
50%
older patients were more likely to lose three or more lines of vision
Study
81%
trials where mask air leaks were detected blowing toward the eyes
Cohort Study
13.5%
Central retinal artery peak blood-flow speed was 13.5% lower in diabetic patients.
Study
379 +/- 156 microm
lower thickness in the central retina, checked with an eye scan
Case Report
9 of 10 eyes
eyes had better measured vision after treatment